0 Shares 86 Views

Moderna CEO expects COVID-19 vaccine interim results in November: WSJ

Oct 20, 2020
0 87
Moderna CEO expects COVID-19 vaccine interim results in November: WSJModerna CEO expects COVID-19 vaccine interim results in November: WSJ
FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts

(Reuters) – Moderna Inc Chief Executive Officer Stéphane Bancel expects interim results from its COVID-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported https://www.wsj.com/articles/moderna-ceo-expects-covid-19-vaccine-interim-results-in-november-11603164001?mod=searchresults&page=1&pos=1 on Monday.

Speaking at the newspaper’s annual Tech Live conference, Bancel also said sufficient interim results from the study takes longer to get and that the government’s permission to use the vaccine may not come until next year.

The first interim analysis of the vaccine’s efficacy will happen when 53 people in the entire study get symptomatic COVID-19, the report said.

“That first analysis is likely to occur in November, but it’s hard to predict exactly which week because it depends on the cases, the number of people getting sick,” the report quoted Bancel as saying.

Bancel had told Financial Times https://www.ft.com/content/9b242ecc-3dce-4534-9171-cdf624468a2a last month that Moderna would not be ready to apply for emergency use of its COVID-19 vaccine before Nov. 25 at the earliest.

Bancel also highlighted that a ramping up of production is a challenge. “If one ingredient is missing, we cannot make the vaccine,” as per the Journal’s report.

Moderna is on track to produce 20 million doses of its experimental vaccine by the end of the year, the company had said last month, adding that 25,296 participants had enrolled out of a planned 30,000 in its late-stage study.

Drugmakers are racing to develop a COVID-19 vaccine, with more than 150 potential vaccines being developed and tested globally.

Besides Moderna, Pfizer Inc, and AstraZeneca Plc, among others, are front-runners to develop the vaccine.

(Reporting by Anirudh Saligrama in Bengaluru; editing by Uttaresh.V)

You may be interested

Official sources: Iraq trains US-sanctioned militia leader for army position
News
29 views
News
29 views

Official sources: Iraq trains US-sanctioned militia leader for army position

Webby - November 27, 2020

The Iraqi military is training a former member of an Iran-backed militia, who is under US sanctions for killing protesters, to become a high-ranking officer in the…

News
15 views

Exclusive: Iraq trains U.S.-sanctioned militia leader for army position – sources

Webby - November 27, 2020

By John Davison, Ahmed Rasheed5 Min ReadBAGHDAD (Reuters) - The Iraqi military is training a former member of an Iran-backed militia, who is under U.S. sanctions for…

Trump plans trip to Georgia amid his election battle
News
33 views
News
33 views

Trump plans trip to Georgia amid his election battle

Webby - November 27, 2020

President Trump said he likely would travel to Georgia on Saturday to campaign for Sens. Kelly Loeffler and David Perdue ahead of their runoff elections. He called the Georgia…

Leave a Comment

Most from this category